血浆Septin9基因甲基化检测在胃肠道病变中的临床应用价值评价
DOI:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

基金项目:


Evaluation for clinical application of methylated Septin 9 test in plasma of gastrointestinal diseases
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的?探讨血浆Septin9基因甲基化在胃肠道病变进展过程中的临床应用价值。方法?纳入2017年5月至2020年11月在福建医科大学附属第一医院行血浆Septin9基因甲基化检测(PCR荧光法)的受检者(包括结直肠癌和胃癌患者、消化系统良性病变患者及无疾病证据受检者)2 128例,收集相关临床资料,并进行ROC曲线分析。结果?术前结直肠癌和胃癌患者、消化系统良性病变患者、无疾病证据受检者血浆Septin9基因甲基化的阳性率分别为57.67%、43.71%、17.72%和4.88%。与无疾病证据受检者组相比较,术前结直肠癌和胃癌患者Septin9基因甲基化检测的敏感性分别为57.71%和43.71%,特异性分别为95.12%和95.12%。临床分期为Ⅲ~Ⅳ期的结直肠癌(68.92%)和胃癌(48.80%)患者的血浆Septin9基因甲基化的阳性率高于Ⅰ~Ⅱ期结直肠癌(50.51%)和胃癌(18.82%)患者,术前行该检测的结直肠癌(57.76%)和胃癌(43.71%)患者的阳性率亦高于术后行该检测的结直肠癌(31.45%)和胃癌(33.76%)患者,且有63.33%结直肠癌与69.23%胃癌患者在术后该指标由阳性转变为阴性。ROC曲线分析结果表明,单独血浆Septin9基因甲基化在筛查结直肠癌患者与结直肠良性病变患者或无疾病证据受检者组中ROC曲线下面积(AUCROC)分别为0.681和0.764,在筛查胃癌患者与胃良性病变患者或无疾病证据受检者组中的AUCROC分别为0.649和0.694。在筛查结直肠癌与结直肠良性病变患者组中,Septin9联合癌胚抗原检测的AUCROC可提高至0.789。结论?血浆Septin9基因甲基化检测在结直肠癌和胃癌中具有一定的诊断价值,但仍需结合其他的诊断方法。

    Abstract:

    Objective?To investigate the values in clinical application of plasma methylated?Septin9?test in gastrointestinal diseases.?Methods?The data were collected retrospectively from the First Affiliated Hospital of Fujian Medical University from May 2017 to November 2020. A total of 2 128 recipients, including the patients with colorectal cancer (CRC), gastric cancer (GC) and benign digestive diseases, as well as the recipients who were no evidences of diseases (NED), received plasma methylated?Septin9?test (PCR-fluorescent probe method). The relevant clinical data were collected and ROC curve analysis was performed.?Results?The positive rates of plasma methylated?Septin9?test in the pre-operative patients with CRC, GC and benign digestive diseases as well as the NED recipients were 57.67%, 43.71%, 17.72% and 4.88%, respectively. Compared with NED recipients, the sensitivity of plasma methylated?Septin9?test in pre-operative patients with CRC and GC were 57.71% and 43.71%, while the specificity were 95.12% and 95.12%. Furthermore, the positive rates methylated?Septin9?test were increased in the CRC patients (68.92%) and GC patients (48.80%) with TNM stage Ⅲ and Ⅳ, which were more than those in the CRC patients (50.51%) and GC patients (18.82%) with TNM stage Ⅰ and Ⅱ. Similarly, the positive rates in the CRC patients (57.76%) and GC patients (43.71%) before surgery were significantly higher than those in the CRC patients (31.45%) and GC patients (33.76%) after surgery, respectively. After surgery, the results of plasma methylated?Septin9?tests changed from positive to negative in 63.33% CRC patients and 69.23% GC patients. ROC curve analysis demonstrated that the area under the curves (AUCROC) of plasma methylated?Septin9?test between CRC patients and the benign colorectal disease patients or NED recipients were 0.681 or 0.764, while the AUCROC?between GC patients and with gastric disease patients or NED recipients were 0.649 and 0.694 respectively. The combined detections of methylated?Septin9?and carcinoembryonic antigen increased AUCROC?to 0.789 in the patients with CRC and benign colorectal diseases group.?Conclusion?Plasma methylated?Septin9?test have diagnostic values for CRC and GC. However, additional diagnostic methods should still be required.

    参考文献
    相似文献
    引证文献
引用本文

王炳龙,汤纪丰,俞子晴,江仁权,何毓闵,林锦骠,欧启水.血浆Septin9基因甲基化检测在胃肠道病变中的临床应用价值评价[J].临床检验杂志,2021,39(3):182-187

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2020-12-19
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2021-05-17
  • 出版日期: 2021-03-28
您是第位访问者  苏ICP备12051282号-1
主管单位:江苏省医学会  出版单位:临床检验杂志
单位地址:江苏省南京市中央路42号  邮编:210008
电话:025-83620683 E-MAIL:lcjyzz@163.com
技术支持:北京勤云科技发展有限公司
关闭